Research shows neonatal stem cells could be used as treatment for Crohn’s disease
July 31, 2023Research and Development Crohn’s disease, Gastrointestinal tract, Stem cells, gastrointestinal
Recent studies from the Ann & Robert H Lurie Children’s Hospital in Chicago have discovered that human neonatal cardiac-derived mesenchymal …
FDA approves a second OTC naloxone nasal spray
July 31, 2023Medical Communications FDA, Nasal Spray, OTC, OTC Products, naloxone, opioids
The US Food and Drug Administration (FDA) has announced that it has approved RiVive, 3mg naloxone hydrochloride nasal spray for …
Biogen to acquire Reata Pharmaceuticals
July 31, 2023Business Services Biogen, Neurology, Reata Pharmaceuticals, acquisition
Biogen and Reata Pharmaceuticals have announced that they have entered a definitive agreement under which Biogen will acquire Reata for …
Eli Lilly shares data from two phase 3 tirzepatide studies
July 28, 2023Research and Development Eli Lilly, Obesity, clinical trial, tirzepatide, weight loss
Eli Lilly has announced results from its two phase 3 tirezepatide studies in adult patients with obesity or who are …
AstraZeneca’s Alexion partners with Pfizer for rare disease therapies
July 28, 2023Research and Development Alexion, AstraZeneca, Pfizer, Rare Diseases, genomics, rare disease
Alexion, AstraZeneca’s Rare Disease division, has announced that it has entered a definitive purchase and licence agreement with Pfizer. The …
Hummingbird Bioscience initiates phase 1b trials for sqNSCLC
July 27, 2023Research and Development Hummingbird Bioscience, Omico, Oncology, clinical trials, sqNSCLC
Hummingbird Bioscience has announced the initiation of two phase 1b clinical trials taking place in Australia. The trials will evaluate …
American Heart Association awards $2.1m to research link between migraine, strokes and CVD
July 27, 2023Research and Development American Heart Association, Cardiology, cvd, migraine, stroke
The American Heart Association has announced that it will fund seven new scientific research studies to learn more about the …
Amarin gains positive opinion from Spanish Drug Pricing Committee for national reimbursement of Vazkepa in Spain
July 26, 2023Sales and Marketing Amarin, Cardiology, Spanish Drug Pricing Committee, Vazkepa, cardiovascular
Amarin has announced that the Spanish Drug Pricing Committee has recommended the national reimbursement of Vazkepa (icosapent ethyl) in Spain …
Biovian announces investment in manufacturing facility in Finland
July 26, 2023Manufacturing and Production Biovian, Pharmacy, facility, manufacturing
Biopharmaceutical based contract development and manufacturing organisation (CDMO) Biovian OY has announced an investment of over €50m to expand its …
AbbVie announces first patient dosed in phase 3 trial of upadacitinib in hidradenitis suppurativa
July 25, 2023Research and Development AbbVie, Dermatology, HS, Rinvoq, clinical trial, upadacitinib
AbbVie has announced that the first patient has been dosed in its phase 3 Step-Up trial assessing Rinvoq (upadacitinib) for …
Bavarian Nordic announces RSV vaccine did not meet all primary endpoints in phase 3 trial
July 25, 2023Medical Communications Bavarian Nordic, Infections and infestations, RSV, Vaccine, clinical trial
Bavarian Nordic has announced that its phase 3 clinical trial of MVA-BN, its respiratory syncytial virus (RSV) vaccine candidate for …
ViiV Healthcare gains positive CHMP opinion for cabotegravir for HIV prevention
July 24, 2023Medical Communications CHMP, EMA, HIV, HIV/AIDS, ViiV Healthcare, cabotegravir
GSK has announced that ViiV Healthcare has received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal …
Alnylam and Roche partner for RNAi therapeutic for treatment of hypertension
July 24, 2023Research and Development Alnylam, Cardiology, Roche, hypertension, rnai, zilebesiran
Alnylam Pharmaceuticals has announced that it has entered a strategic agreement with Roche for the development and commercialisation of zilebesiran, …
Aevice Health gains FDA clearance for respiratory monitoring platform
July 21, 2023Research and Development Aevice Health, Devices, FDA, respiratory monitoring
Remote respiratory monitoring solutions company Aevice Health has announced that it has received clearance from the US Food and Drug …
BioIVT acquires PrecisionMed for neurology and oncology research
July 21, 2023Sales and Marketing Neurology, Oncology, neurology, oncology
BioIVT has announced that it has acquired PrecisionMed, a leading supplier of high-quality human biological material for genetics, drug discovery …
WHO releases Medical Product Alert for contaminated cough syrup
July 20, 2023Medical Communications Pharmacy, WHO, cough syrups, medical product alert, world health organization
The World Health Organization (WHO) has shared a Medical Product Alert for an additional contaminated cough syrup medicine identified in …
Pfizer shares new data from phase 2 trial for GBS maternal vaccine candidate
July 20, 2023Research and Development Immunology, Pfizer, Vaccine, clinical trial
Pfizer has announced new data from its phase 2 study which assessed its hexavalent capsular polysaccharide (CPS) conjugate Group B …
Santhera closes exclusive license agreement with Catalyst Pharmaceuticals for Vamorolone
July 19, 2023Medical Communications License Agreement, Musculo-skeletal disorder, Vamorolone, catalyst, santhera
Santhera Pharmaceuticals has announced the closing of its exclusive North American license agreement for vamorolone with Catalyst Pharmaceuticals. The agreement …
Renibus Therapeutics announces $47m financing for phase 3 trial
July 19, 2023Business Services Cardiology, Financing, Renibus Therapeutics, clinical trial
Clinical stage biopharmaceutical company Renibus Therapeutics has announced that it has raised $47m from the initial closing of its Series …
Eli Lilly shares results from phase 3 trial of donanemab for Alzheimer’s treatment
July 18, 2023Research and Development Alzheimer's, Eli Lilly, Neurology, clinical trial, donanemab
Eli Lilly has presented full results from the phase 3 TRAILBLAZER-ALZ 2 study which assessed donanemab for the treatment of …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
